Atypical  	Atypical  	 JJ	B-NP
subtrochanteric  	subtrochanteric  	 JJ	I-NP
fractures  	fractures  	 NN	I-NP
after  	after  	 IN	O
long-term  	long-term  	 JJ	O
bisphosphonate  	bisphosphonate  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
There  	There  	 EX	O
have  	have  	 VBP	O
been  	been  	 VBN	O
many  	many  	 JJ	O
reports  	reports  	 NNS	O
published  	published  	 VBN	O
in  	in  	 IN	O
recent  	recent  	 JJ	O
years  	years  	 NNS	O
on  	on  	 IN	O
atypical  	atypical  	 JJ	O
subtrochanteric  	subtrochanteric  	 JJ	B-NP
fractures  	fractures  	 NN	I-NP
after  	after  	 IN	O
long-term  	long-term  	 JJ	O
bisphosphonates  	bisphosphonates  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
description  	description  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
few  	few  	 JJ	O
series  	series  	 NN	O
of  	of  	 IN	O
cases 	cases 	 NNS	O
,  	,  	 ,	O
fractures  	fractures  	 VBG	O
of  	of  	 IN	O
typical  	typical  	 JJ	O
clinical  	clinical  	 JJ	B-NP
course  	course  	 NN	I-NP
and  	and  	 CC	O
radiological  	radiological  	 JJ	B-NP
image  	image  	 NN	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
documented 	documented 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
fractures  	fractures  	 NNS	O
are  	are  	 VBP	O
estimated  	estimated  	 VBN	O
as  	as  	 IN	O
very  	very  	 RB	O
rare  	rare  	 JJ	O
( 	( 	 -LRB-	O
2.3  	2.3  	 CD	O
per  	per  	 IN	O
10,000  	10,000  	 CD	O
patient-years 	patient-years 	 NN	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
a  	a  	 DT	O
subsequent  	subsequent  	 JJ	O
use  	use  	 NN	O
of  	of  	 IN	O
steroids  	steroids  	 NNS	O
or  	or  	 CC	O
proton  	proton  	 NNS	O
pump  	pump  	 VBP	O
inhibitors  	inhibitors  	 VBN	O
with  	with  	 IN	O
bisphosphonates  	bisphosphonates  	 NNS	B-NP
may  	may  	 MD	O
increase  	increase  	 VB	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
fracture  	fracture  	 JJ	B-NP
occurrence 	occurrence 	 NN	I-NP
.  	.  	 .	O
